Royalty Pharma plc filings document the company’s biopharmaceutical royalty business, public equity structure, governance, financing activity, and material events. Form 8-K reports furnish quarterly and annual results, including Portfolio Receipts, Royalty Receipts, operating cash flow, guidance, dividends, and developments affecting royalty and funding arrangements.
Regulation FD and material-agreement disclosures describe royalty transactions, synthetic royalty funding, senior secured loan arrangements, and portfolio-related clinical or regulatory events. Other filings cover Class A ordinary shares listed on Nasdaq, senior note issuances and related guarantees, annual meeting matters, board and compensation governance, shareholder voting items, and changes involving directors or officers.
Royalty Pharma plc officer George Lloyd reported a planned sale of 100,462 common shares by George Lloyd Roth IRA, with an aggregate market value of $4,600,154.98 and an approximate sale date of March 18, 2026. Goldman Sachs & Co. LLC is identified as the broker. The sale is described as being under a selling plan dated August 20, 2025, intended to comply with Rule 10b5-1(c).
Royalty Pharma plc executive vice president and CFO Terrance P. Coyne reported indirect open-market sales of a total of 34,791 Class A ordinary shares of Royalty Pharma plc on March 2, 2026. The sales were made by entities TPC RP 2021, LLC and TPC RP EPA1 LLC at weighted average prices around $46.67 and $47.01 per share, in multiple transactions within disclosed price ranges. All reported transactions were effected under a pre-arranged Rule 10b5-1 trading plan adopted on August 8, 2025.
Royalty Pharma plc (RPRX) officer George Lloyd reported a proposed sale of 136,980 common shares through his Roth IRA, with an aggregate market value of $6,496,961.4 and an approximate sale date of March 4, 2026. The sale is connected to a selling plan dated August 20, 2025, intended to comply with Rule 10b5-1(c). The notice also lists recent sales by GWL 2013 NG LLC and GWL 2014 G LLC, including 123,965 shares sold by GWL 2013 NG LLC on January 21, 2026, for gross proceeds of $4,913,885.82.
Royalty Pharma plc (RPRX) is named in a notice by officer Terrance Coyne for the proposed sale of 34,791 common shares, with an aggregate market value of $1,651,528.77. The shares are listed for sale by TPC RP 2021 LLC (32,916 shares) and TPC RP EPA1 LLC (1,875 shares).
The notice lists March 2, 2026 as the approximate sale date and says the sales are in connection with a plan dated August 8, 2025, intended to comply with Rule 10b5-1(c).
Royalty Pharma plc insider reporting shows entities associated with EVP & CFO Terrance P. Coyne selling Class A Ordinary Shares of the company. On the reported date, TPC RP 2021, LLC and TPC RP EPA1 LLC together sold 34,791 shares in open-market transactions at a weighted average price of $45.3165 per share.
The filing notes these transactions were carried out under a pre-established Rule 10b5-1 trading plan adopted on August 8, 2025, which automates sales based on preset instructions. A footnote explains the reported sale price is an average, with individual trades executed between $44.97 and $45.60 per share.
Royalty Pharma plc officer Terrance Coyne reports a proposed sale for his account of 34,791 common shares, to be sold through TPC RP 2021 LLC (32,916 shares) and TPC RP EPA1 LLC (1,875 shares). The reported aggregate market value is $1,581,946.77, and the approximate sale date is February 23, 2026. The sales are connected to a selling plan dated August 8, 2025, described as intended to comply with Rule 10b5-1(c). Goldman Sachs & Co. LLC is identified as the broker.
Royalty Pharma plc’s Class A shareholder updates 13D stake. R & H Trust Co. (Guernsey) Limited and Achille G. Severgnini report they may be deemed to beneficially own 24,223,082 Class A shares, representing 5.7% of Royalty Pharma’s outstanding Class A shares as of February 19, 2026.
The filing details holdings through sub-funds MGG Strategic and GG Strategic and extensive beneficial ownership disclaimers by the boards, trust beneficiaries, trustee and protector. It also notes prior sales and facility agreements that reduced pledged collateral shares and adjusted committed and uncommitted credit facility amounts.
Capital International Investors, a division of Capital Research and Management Company and affiliated investment management entities, reports beneficial ownership of 32,745,526 shares of Royalty Pharma PLC common stock, representing 7.7% of the 427,247,489 shares believed outstanding as of the event date.
The firm has sole voting power over 32,581,425 shares and sole dispositive power over 32,745,526 shares, with no shared voting or dispositive power. The securities are certified as acquired and held in the ordinary course of business, not for the purpose of changing or influencing control of Royalty Pharma.
Royalty Pharma CEO Pablo G. Legorreta acquired 157,828 Class A Ordinary Shares at $0.00 per share on February 11, 2026 through the settlement of equity performance awards. Following this exempt award, he directly holds 1,098,783 Class A Ordinary Shares.
He also has indirect ownership through various family trusts and entities, including Legorreta Children 2002 Trust, GST-Exempt Legorreta family trusts, Legorreta Investments LLC, Tata MC 35 Ltd., and accounts for spouse and children. In addition, he and related vehicles hold limited partnership interests in RPI US Partners 2019, LP exchangeable into 73,495,660 Class A Ordinary Shares and Class E Ordinary Shares of Royalty Pharma Holdings Ltd exchangeable into 13,356,742 Class A Ordinary Shares, with the Class E shares subject to vesting conditions.
Royalty Pharma plc executive vice president and CFO Terrance P. Coyne reported an indirect equity award of Class A Ordinary Shares. On February 11, 2026, an affiliated entity, TPC RP EPA1 LLC, acquired 26,626 Class A shares at $0 per share in an exempt transaction under Rule 16b-3 tied to the settlement of equity performance awards. Following this grant, TPC RP EPA1 LLC holds 49,511 Class A shares indirectly for Coyne. The filing also notes additional indirect holdings through related LLCs and retirement accounts, plus partnership and Class E Ordinary Share interests exchangeable into 6,448,180 and 1,807,277 Class A shares, respectively, with the Class E interests subject to vesting conditions.